Treatment News : Tobira Launches Phase II Study of Entry Inhibitor Cenicriviroc

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 24, 2011

Tobira Launches Phase II Study of Entry Inhibitor Cenicriviroc

Tobira Therapeutics is recruiting for a Phase IIb study of its CCR5/CCR2 entry inhibitor cenicriviroc (TBR-652). It is hoped that cenicriviroc will not only offer people a new antiretroviral (ARV) option to keep HIV in check, but that it will also prove useful in reducing the cellular inflammation that scientists believe is behind a host of health problems.

Cenicriviroc is from a class of drugs that blocks the CCR5 coreceptor on CD4 cells, thus making them resistant to HIV infection. It is in the same class of drugs as Selzentry (maraviroc) but may be used once-daily instead of twice-daily.

Cenicriviroc also has another unique attribute. In addition to blocking the CCR5 coreceptor, it also blocks another coreceptor called CCR2, which is involved in inflammatory diseases such as rheumatoid arthritis. In recent years, researchers have shown that cellular inflammation, even in people whose HIV is well controlled by ARV therapy, may contribute to a number of health problems, including cardiovascular disease. It is hoped, though it will take time to prove this, that cenicriviroc will be a dual-purpose drug—fighting HIV directly while also reducing HIV-related inflammation.

According to Tobira press materials, the new study will pit cenicriviroc against Sustiva (efavirenz), both of them paired with Truvada (tenofovir plus emtricitabine). Tobira will be studying two doses of cenicriviroc, 100 milligrams (mg) and 200 mg once-daily.

“This study is based on the strength of the cenicriviroc Phase IIa proof of concept, pharmacokinetic and safety findings that were presented at key HIV/AIDS conferences and published in peer‐reviewed journals,” said Melanie Thompson, MD, of the AIDS Research Consortium of Atlanta, and a lead investigator in the Phase IIb study. “The study will further explore cenicriviroc’s antiviral activity and safety as well as effects on immunologic and inflammatory biomarkers, including the effects of CCR2 receptor inhibition in HIV‐1 infected patients.”

To learn more about the cenicriviroc study, visit the clinical trials database run by the National Institutes of Health (NIH).

Search: Cenicriviroc, TBR-652, Tobira, entry inhibitor, CCR5, CCR2, inflammation, Phase IIb study, Sustiva, efavirenz

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.